[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Thammasat University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":310},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,75,101,130,154,176,200,217,248,276],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100652832","efficacy-of-oral-nutritional-supplement-in-femoral-neck-fracture-patients-undergoing-hip-arthroplasty-100652832",false,"NCT07780006","Efficacy of Oral Nutritional Supplement in Femoral Neck Fracture Patients Undergoing Hip Arthroplasty","Efficacy of Oral Nutritional Supplement in Femoral Neck Fracture Patients Undergoing Hip Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Femoral neck fracture patients undergoing hip arthroplasty (Total hip arthroplasty or bipolar hemiarthroplasty)\n* Age ≥ 65 years\n* American Society of Anesthesiologists (ASA) class I-III\n* Participants understand and consent to the protocol of the trial\n\nExclusion Criteria:\n\n* Pathologic fracture or high impact fracture\n* Morbid obesity (Body mass index \\> 40)\n* Chronic kidney disease (Chronic kidney disease stage \\> 3b or estimated glomerular filtration rate (eGFR) \\\u003C 30)\n* Thyroid disease or endrocrinopathy\n* Gastrointestinal intolerance preventing oral supplementation or Malabsorption syndromes\n* Malignancy with radiotherapy or chemotherapy\n* Cognitive disorder\n* Decompensated Liver Disease or Cirrhosis Child-Pugh Class B-C\n* Known allergy\u002Fintolerance to milk or other supplement ingredients","ALL","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aim to compare the efficacy of oral nutritional supplementation (ONS) in femoral neck fracture patients undergoing hip arthroplasty compared with placebo. The hypothesis is \"Oral nutritional supplement with Beta-hydroxy-beta-methylbutyrate (HMB) can improve muscle strength in femoral neck fracture patients undergoing hip arthroplasty\".\n\nFemoral neck fracture patients aged more than 65 years will be enrolled and allocated into 2 groups\n\n* ONS group: Oral nutritional supplement (Ensure® Plus Advance) 2 serves \u002F day x 30 days + Standard oral intake\n* Control group: Standard oral intake\n\nPrimary outcome is Grip strength, assessed using hand dynamometer on admission and 2, 6, 12 weeks postoperatively.\n\nSecondary outcomes are\n\n* Serum albumin assessed on admission and 2, 6, 12 weeks postoperatively\n* Barthel index assessed at 2, 6, 12 weeks postoperatively\n* Mini Nutritional Assessment (MNA), Geriatric Nutritional Risk Index (GNRI) assessed at 2, 6, 12 weeks postoperatively\n* Length of stay (day)\n* Time up and go (TUG), assessed at 2, 6, 12 weeks postoperatively\n* Oxford hip score (OHS), assessed at 2, 6, 12 weeks postoperatively\n* Complications, rate of readmission, mortality rate assessed until 3 months",[26,27,28],"Femoral Neck Fractures","Geriatric Hip Fracture","Hip Fracture, Post Surgery Recovery, Muscle Resilience",[30,31,32],"Femoral neck fractures","Oral nutritional supplementation","HMB","NOT_YET_RECRUITING","2026-08-18",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":20},"2026-10",{"date":41,"type":20},"2027-12",{"name":43,"class":44},"Thammasat University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100647438","phase-4-benfotiamine-versus-vitamin-b1-6-12-for-diabetic-peripheral-neuropathy-100647438","NCT07708233","Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy","A 12-Week Double-blind Randomized Controlled Study; Comparing the Efficacy of Benfotiamine and Vitamin b1-6-12 in Alleviating Numbness, Sensory Neuropathy Symptoms and Pain in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of diabetic peripheral neuropathy confirmed by a physician based on the following ICD-10 codes: E11.42: Type 2 diabetes mellitus with diabetic polyneuropathy; or E11: Type 2 diabetes mellitus, combined with either:\n\nM79.2: Neuralgia and neuritis, unspecified; or G62.9: Polyneuropathy, unspecified.\n\n* Presence of sensory neuropathy symptoms assessed using the Neuropathy Total Symptom Score-6 (NTSS-6), with: Total NTSS-6 score ≥1; and Numbness symptom score (NTSS-6 item 6) ≥1.\n* No evidence of vitamin B12 deficiency, defined as a serum vitamin B12 level ≥200 pg\u002FmL (148 pmol\u002FL).\n* provide informed consent and participate in the study.\n\nExclusion Criteria:\n\n* Presence of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltose malabsorption.\n* Adjustment of doses of medications used for neuropathic pain control within 6 weeks prior to study enrollment, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, or other neuropathic pain medications.\n* Presence of other conditions that may affect diabetic peripheral neuropathy or neuropathic pain, including:\n\n  * Chemotherapy-induced peripheral neuropathy due to neurotoxic agents within 6 months prior to enrollment, including vinca alkaloids, taxanes, platinum-based agents, proteasome inhibitors, thalidomide, brentuximab vedotin, or ado-trastuzumab emtansine.\n  * HIV\u002FAIDS with any of the following: Current or previous treatment with didanosine, stavudine, or zalcitabine; CD4 count \\\u003C200 cells\u002Fmm³; or HIV viral load \\>1,000 copies\u002FmL.\n  * Drug-induced polyneuropathy (ICD-10: G62.0).\n  * Polyneuropathy due to other toxic agents (ICD-10: G62.2).\n  * Alcoholic polyneuropathy (ICD-10: G62.1).\n  * Fibromyalgia (ICD-10: M79.7).\n  * Planned surgery within 3 months prior to or during the study period.\n  * Previous pain-relief procedures, including:\n* Transcutaneous electrical nerve stimulation (TENS) or temporary peripheral nerve stimulation (PNS) within 1 year prior to enrollment;\n* Permanent PNS;\n* Pulsed radiofrequency or radiofrequency ablation within 6 months prior to enrollment;\n* Botulinum toxin injection for neuropathic pain relief within 12 weeks prior to enrollment.\n* Adjustment of glucose-lowering medication doses or HbA1c \\>8% within 3 months prior to study enrollment.\n* Pregnancy, planned pregnancy within 3 months, or currently breastfeeding.\n* Inability to attend scheduled study visits in person or through telemedicine follow-up as required by the study protocol.\n* Known allergy or hypersensitivity to benfotiamine or any component of benfotiamine, vitamin B1, vitamin B6, or vitamin B12.\n* Previous use of benfotiamine and\u002For vitamin B1-6-12 discontinued less than 7 days before study enrollment.\n* Current use of vitamin B6 supplementation or medications containing vitamin B6 at a dose \\>100 mg\u002Fday.","18 Years",{"count":55,"type":20},66,[57],"PHASE4","The purpose of this clinical trial is to compare the efficacy of benfotiamine with vitamin B1-6-12 in reducing sensory neuropathy symptoms, numbness and pain in patients with diabetic peripheral neuropathy.\n\nThe main questions this study aims to answer are:\n\n* Does benfotiamine reduce overall sensory neuropathy symptoms more effectively than vitamin B1-6-12?\n* Does benfotiamine reduce numbness more effectively than vitamin B1-6-12?\n* Does benfotiamine reduce pain more effectively than vitamin B1-6-12?\n\nResearchers will compare benfotiamine with vitamin B1-6-12 in a double-blind study. Both treatments will be manufactured as visually identical study medications to maintain blinding.\n\nThe study will evaluate whether benfotiamine provides greater improvement in sensory neuropathy symptoms, numbness, and pain than vitamin B1-6-12 in patients with diabetic peripheral neuropathy.\n\nParticipants will:\n\n* undergo screening for vitamin B12 deficiency before enrollment. Patients with vitamin B12 deficiency will not be eligible for participation.\n* randomly assigned to receive either benfotiamine or vitamin B1-6-12, taken orally twice daily for 3 months.\n* attend two on-site clinic visits (baseline and the end of the study) and complete two telephone follow-up assessments during the study.\n* continue their usual medications throughout the study, provided that no new neuropathic pain medications are initiated and the dose of existing neuropathic pain medications remains unchanged.",[60],"Diabetic Peripheral Neuropathy (DPN)",[62,63,64,65],"benfotiamine","Vitamin B","Daibetic neuropathy","diabetic peripheral neuropathy","RECRUITING","2026-07-18",{"date":69,"type":37},"2026-07-21",{"date":71,"type":37},"2026-07-14",{"date":73,"type":20},"2027-06-30",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100647563","comparison-of-the-concordance-between-digital-marking-and-manual-marking-for-toric-intraocular-lens-positioning-100647563","NCT07710963","Comparison of the Concordance Between Digital Marking and Manual Marking for Toric Intraocular Lens Positioning","Comparison of the Concordance Between Digital Image-Guided Navigation and Manual Peripheral Corneal Marking for Toric Intraocular Lens Positioning","Inclusion Criteria:\n\n* candidates for uncomplicated cataract surgery\n\nExclusion Criteria:\n\n* irregular corneal astigmatism, lens subluxation, uveitis, glaucoma, trauma, history of retinal disease or optic neuropathy, previous intraocular or corneal surgery and corneal disease that could not be evaluated by the ARGOS or VERION systems","90 Years",{"count":84,"type":20},100,"OBSERVATIONAL","This cross-sectional comparative study evaluated patients from a single cataract center. In each eye, manual horizontal meridian axis line was marked on the cornea using the manual peripheral corneal marking technique (Horizontal Slit Beam Marking ), while the Verion digital image-guided navigation system provided a reference axis fixed at the horizontal meridian (0°\u002F180°). The primary outcome measure was the difference in degrees between the digital marker and the manual marker horizontal meridian as measured intraoperatively. Agreement was assessed using Bland-Altman analysis, reporting the mean bias (systematic error) and 95% limits of agreement (LoA, mean ± 1.96 SD). A misalignment of ±10° was defined as the threshold of clinical significance.",[88],"Cataract Surgeries",[90,91,92],"manual marking","digital marking","toric intraocular lens","2026-07-13",{"date":95,"type":37},"2026-07-17",{"date":97,"type":20},"2026-07-10",{"date":99,"type":20},"2026-10-30",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100635141","gina-p-and-act-p-scores-for-assessing-asthma-control-100635141","NCT07548827","GINA-P and ACT-P Scores for Assessing Asthma Control","Inclusion Criteria:\n\n* Asthma\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Inability to perform spirometry test",{"count":108,"type":20},144,"The goal of this observational study is to determine the accuracy of GINA-P and ACT-P scores in assessing asthma control levels among adults with asthma.\n\nThe main question the study aims to answer is:\n\nHow accurate are the GINA-P and ACT-P scores in assessing asthma control levels among adults with asthma? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing.",[111],"Asthma",[113,114,115,116,117,118,119,120],"asthma","asthma control","pulmonary function","bronchodilator response","Asthma Control Test","Global Initiative for Asthma","ACT-P","GINA-P","2026-04-16",{"date":123,"type":37},"2026-04-23",{"date":125,"type":20},"2026-05-01",{"date":127,"type":20},"2026-12-31",{"name":43,"class":44},2,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":45},"100618162","remission-in-adults-with-severe-asthma-in-thailand-100618162","NCT07328035","Remission in Adults With Severe Asthma in Thailand","Inclusion Criteria:\n\n* severe asthma\n* age 18 years or older\n\nExclusion Criteria:\n\n* inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test",{"count":137,"type":20},230,"The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand.\n\nThe main question the study aims to answer is:\n\nWhat is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.",[140,141],"Severe Asthma","Asthma Control Level",[113,143,144,145,146,147],"remission","Thailand","severe","FeNO","blood eosinophil count",{"date":149,"type":37},"2026-04-17",{"date":151,"type":37},"2026-01-01",{"date":127,"type":20},{"name":43,"class":44},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100622459","chronic-obstructive-pulmonary-disease-and-asthma-in-workers-at-navanakorn-industrial-zone-thailand-100622459","NCT07383896","Chronic Obstructive Pulmonary Disease and Asthma in Workers at Navanakorn Industrial Zone, Thailand","Inclusion Criteria:\n\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Inability to perform spirometry",true,{"count":162,"type":20},310,"The goal of this observational study is to determine the prevalence of asthma and chronic obstructive pulmonary disease (COPD) among workers in an industrial zone in Thailand.\n\nThe main question the study aims to answer is:\n\nWhat is the prevalence of asthma and COPD among workers in Thailand? Participants will complete a questionnaire on respiratory symptoms and undergo pulmonary function testing.",[111,165],"COPD",[113,165,115,167,168,144],"worker","industry","2026-04-15",{"date":149,"type":37},{"date":172,"type":37},"2025-09-01",{"date":174,"type":20},"2026-05-31",{"name":43,"class":44},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":129},"100621878","comparative-study-of-cpap-predictive-equations-and-in-laboratory-manual-titration-in-thai-patients-with-obstructive-sleep-apnea-100621878","NCT07376343","Comparative Study of CPAP Predictive Equations and In-laboratory Manual Titration in Thai Patients With Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Suspected OSA\n* Undergoing an in-laboratory sleep study\n\nExclusion Criteria:\n\n* No indication for in-laboratory manual CPAP titration\n* Failure to determine an optimal CPAP pressure during in-laboratory manual CPAP titration",{"count":183,"type":20},150,"The goal of this observational study is to compare predictive equations for continuous positive airway pressure (CPAP) with in-laboratory manual titration in patients with obstructive sleep apnea (OSA).\n\nThe main question the study aims to answer is:\n\nWhich CPAP predictive equation best predicts the optimal CPAP pressure in OSA patients in Thailand? Participants will undergo an in-laboratory sleep study.",[186],"OSA - Obstructive Sleep Apnea",[188,189,190,191,192,144,193,194],"OSA","obstructive sleep apnea","CPAP","continuous positive airway pressure","equation","sleep test","polysomnography",{"date":149,"type":37},{"date":197,"type":37},"2026-02-01",{"date":127,"type":20},{"name":43,"class":44},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":216,"locationsCount":129},"100619999","remission-in-adults-with-mild-to-moderate-asthma-in-thailand-100619999","NCT07351916","Remission in Adults With Mild-to-moderate Asthma in Thailand","Inclusion Criteria:\n\n* mild-to-moderate asthma\n* age 18 years or older\n\nExclusion Criteria:\n\n* inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test",{"count":207,"type":20},289,"The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.\n\nThe main question the study aims to answer is:\n\nWhat is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.",[111,210,141],"Mild-to-moderate Asthma",[113,114,212,144,143,146,147],"mild-to-moderate asthma",{"date":149,"type":37},{"date":197,"type":37},{"date":127,"type":20},{"name":43,"class":44},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":224,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":45},"100628580","preoperative-high-dose-oral-paracetamol-for-postoperative-analgesia-in-children-undergoing-tonsillectomy-100628580","NCT07463482","Preoperative High-Dose Oral Paracetamol for Postoperative Analgesia in Children Undergoing Tonsillectomy\"","Effect of Preoperative Oral Paracetamol Loading Dose Versus Standard Dose on Postoperative Opioid Consumption in Pediatric Tonsillectomy With Multimodal Analgesia: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Children aged 3 to 15 years\n2. ASA physical status I-III\n3. Scheduled for elective tonsillectomy with or without adenoidectomy\n\nExclusion Criteria:\n\n1. Known allergy or contraindication to paracetamol or any agents in the study protocol\n2. Chronic opioid use","3 Years","15 Years",{"count":227,"type":20},54,[23],"This randomized clinical trial compares two different preoperative doses of oral paracetamol (acetaminophen) in children undergoing elective tonsillectomy. The aim is to determine whether a higher loading dose (30 mg\u002Fkg) decreases the need for opioid rescue medication after surgery compared with the standard dose (15 mg\u002Fkg), when used as part of a multimodal pain management approach. Children aged 3 to 15 years will be randomly assigned to receive either 30 mg\u002Fkg or 15 mg\u002Fkg of oral paracetamol before surgery. All participants will receive the same standard anesthesia and postoperative pain management. The primary outcome is the total amount of rescue opioid (fentanyl) required during the first 12 hours after surgery. Secondary outcomes include postoperative pain scores and the occurrence of side effects such as nausea and vomiting. This study seeks to determine whether a higher initial dose of paracetamol offers additional clinical benefits in pediatric tonsillectomy with multimodal analgesia.",[231,232],"Post Operative Analgesia","Tonsillectomy With or Without Adenoidectomy",[234,235,236,237,238,239],"paracetamol","acetaminophen","tonsillectomy","postoperative analgesia","pediatric anesthesia","multimodal analgesia","2026-03-05",{"date":242,"type":37},"2026-03-11",{"date":244,"type":20},"2026-03",{"date":246,"type":20},"2026-11",{"name":43,"class":44},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":256,"maxAge":82,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":45},"100603745","phase-4-dinalbuphine-sebacate-in-postoperative-pain-control-after-tka-100603745","NCT07140510","Dinalbuphine Sebacate in Postoperative Pain Control After TKA","Effectiveness of Dinalbuphine Sebacate in Postoperative Pain Control Following Total Knee Arthroplasty: A Randomized Double Blinded Placebo-controlled Trial","Naldebain","Inclusion Criteria:\n\n* Osteoarthritic knee patients underwent unilateral primary TKA\n* Age 50-90 years\n* ASA class I-III\n* Participants understand and consent to the protocol of the trial\n\nExclusion Criteria:\n\n* Morbid obesity (BMI\\>40)\n* Knee osteoarthritis from inflammatory knee arthritis, trauma, infection\n* Previous knee surgery\n* Cognitive disorder\n* Liver disease\n* Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate\n* CYP3A4 inhibitor and inducer drugs used","50 Years",{"count":84,"type":20},[57],"To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty",[261,262],"Osteo Arthritis of the Knee","Total Knee Anthroplasty",[264,254,265,266,267],"Dinalbuphine Sebacate","Subacute pain","postoperative pain","total knee arthroplasty","2025-08-18",{"date":270,"type":37},"2025-08-24",{"date":272,"type":20},"2025-10",{"date":274,"type":20},"2026-09",{"name":43,"class":44},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":256,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":129},"100580309","comparison-of-functional-recovery-between-restricted-inverse-kinematic-alignment-and-adjusted-mechanical-alignment-with-robotic-assisted-unilateral-total-knee-arthroplasty-100580309","NCT06835621","Comparison of Functional Recovery Between Restricted Inverse Kinematic Alignment and Adjusted Mechanical Alignment With Robotic-assisted Unilateral Total Knee Arthroplasty.","Comparison of Functional Recovery Between Restricted Inverse Kinematic Alignment and Adjusted Mechanical Alignment With Robotic-assisted Unilateral Total Knee Arthroplasty. A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 50 - 80 years old\n* Diagnosed with primary OA knee and indicated for unilateral total knee arthroplasty with MAKO robotic-assisted knee replacement system\n* ASA classification I-II\n\nExclusion Criteria:\n\n* Valgus deformity\n* KL grading \\> 3 on contralateral knee\n* Unable or difficulty for walking due to comorbidities\n* BMI \\> 40 kg\u002Fm2\n* Previous knee surgery\n* Infection around the knee","80 Years",{"count":285,"type":20},80,[23],"The goal of this clinical trial is to learn if restricted inverse kinematic alignment total knee arthroplasty (restricted iKA TKA) improves functional recovery compared to adjusted mechanical alignment total knee arthroplasty (aMA TKA) in patients undergoing unilateral robotic-assisted total knee arthroplasty by comparing performance-based outcome, 2-minute walk test (2MWT) as a primary outcome. This trial will also assess other outcomes including satisfaction, patient-reported functional outcomes, range of motion, visual analog scale for pain and complication of both techniques. The main question aims to answer is:\n\nIn unilateral robotic-assisted total knee arthroplasty, dose Restricted iKA technique provide better postoperative performance-based outcome compared to aMA technique?\n\nResearchers will compare restricted iKA and aMA technique to determine which technique offers better acceleration in functional recovery and patient satisfaction.\n\nParticipants will:\n\nAfter randomization, participants will allocate to either restricted iKA or aMA technique for unilateral robotic-assisted total knee arthroplasty.\n\nAttend follow-up visits for assessments of 2-minute walk test (Primary outcome), Time up and go test (TUG), VAS for pain, ROM and complete patient-reported functional outcome questionnaires regarding knee function and satisfaction at regular intervals.",[289,290],"OA Knee","TKA",[292,293,294,295,296,297,298,299,300,301],"Osteoarthritis (OA) of the Knee","OA knee","MAKO","Kinematic alignment","Mechanical alignment","Restricted Kinematic alignment","Inversed Kinematic alignment","Inversed Restricted Kinematic alignment","Robotic assist Total Knee Arthroplasty","Adjusted mechanical alignment","2025-02-14",{"date":304,"type":37},"2025-02-19",{"date":306,"type":20},"2025-03",{"date":308,"type":20},"2028-08",{"name":43,"class":44},""]